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OBJECTIVES The purpose of this study was to determine whether antianginal medications modify the
prognostic significance of exercise single photon emission computed tomography (SPECT)
ischemia.
BACKGROUND Antianginal medications (especially beta-adrenergic blocking agents) limit exercise SPECT
ischemia, but it is not known whether such medications also modify the prognostic effect of
exercise SPECT ischemia.
METHODS We included 352 patients with coronary heart disease, who had exercise Tl-201 SPECT and
coronary angiography, and who were initially treated medically. Survival Cox models were
applied in patients for whom classes of antianginal medications taken at exercise SPECT were
the same as those prescribed for follow-up (GI; n 5 136), and in patients for whom new
classes of antianginal medications, including beta-blockers (GII; n 5 79) or not including
beta-blockers (GIII; n 5 113), were added for follow-up.
RESULTS During a mean 5.3 6 1.6 years of follow-up, 45 patients had cardiac death or myocardial
infarction. Variables reflecting necrosis (irreversible defect extent, left ventricular ejection
fraction) and those from coronary angiography provided equivalent prognostic information in
the three groups. In contrast, the SPECT variable reflecting ischemia (reversible defect
extent), which provided comparable prognostic information in GI (p 5 0.005) and GIII (p 5
0.004), lost its prognostic significance (p 5 0.54) in GII, and was associated with a lower
relative risk in GII than in GI or GIII (both p , 0.05).
CONCLUSIONS In patients with coronary heart disease, the introduction of antianginal medications, when
including beta-blockers, appears to have a favorable effect on the deleterious prognostic effect
of exercise ischemia. (J Am Coll Cardiol 1999;34:113–21) © 1999 by the American College
of Cardiology
In patients with coronary heart disease (CHD), exercise
single photon emission computed tomography (SPECT)
provides strong prognostic information (1–9) and allows the
detection of ischemic myocardium, which constitutes a
potential therapeutic target (9–12).
Though a number of antianginal medications can de-
crease the amount of exercise ischemia evidenced on exercise
scintigraphy (13–18), this effect appears particularly marked
for beta-adrenergic blocking agents (13–15), which may
normalize the test (15). In patients with a recent infarction,
it has been observed that medical therapy including beta-
blockers could lead to a reduction in the exercise (Tl-201
SPECT) ischemia which was equivalent to that provided by
coronary angioplasty (19). In terms of primary or secondary
prevention, beta-blockers have also proved beneficial in a
number of trials (20–23), but it is not known whether this
beneficial effect is mediated by their possible influence on
stress ischemia.
The aim of this study was to determine whether the
deleterious effect of exercise (Tl-201 SPECT) ischemia on
the prognosis of patients with CHD could be modified by
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the subsequent introduction of either beta-blocking or
non–beta-blocking antianginal medications.
METHODS
Study population. We retrospectively included all patients
with CHD admitted to our institution from 1982 to 1992,
who underwent, over a six-week period, exercise Tl-201
SPECT and coronary angiography, and who had no myo-
cardial revascularization during the following three months.
Diagnosis of CHD was based on the presence of either
significant ($50%) coronary stenoses or, in patients without
significant coronary artery narrowings, of a documented
myocardial infarction. The exclusion criteria were as fol-
lows: previous history of cardiac surgery or coronary angio-
plasty, congenital or valvular heart disease and hypertrophic
or idiopathic dilated cardiomyopathy. Among the 362
patients who met these criteria, 10 were lost to follow-up,
and the 352 remaining (97%) constituted our study popu-
lation.
Three groups were constituted. The first group, GI,
comprised the patients for whom the classes of antianginal
medications (1, beta-blockers; 2, calcium antagonists; 3,
nitrates or molsidomine) used at the time the exercise
SPECT test was performed were the same as those ordered
at hospital discharge, after the test. The second group, GII,
comprised patients in whom beta-blocking medications
were added between exercise test and hospital discharge.
The third group, GIII, comprised patients in whom classes
of only non–beta-blocking antianginal medications were
added between the test and hospital discharge.
Cardiac catheterization. As previously described (4,24),
coronary angiograms were analyzed visually on end-diastolic
frames by experienced observers. Single-plane X-ray left
ventricular angiography in the 30° right anterior oblique
projection was performed in 342 patients (97%) and used to
measure ejection fraction (area–length method [25]).
Exercise Tl-201 SPECT. The exercise test was performed
in the upright position on a bicycle ergometer. The protocol
was started at 40 W and increased by 30 W every 3 min.
Leads V1, V5 and a VF were continuously monitored,
12-lead electrocardiogram and arterial blood pressure being
recorded at each step.
Exercise end points were physical exhaustion, develop-
ment of angina pectoris, .2 mm ST-segment depression,
sustained ventricular tachyarrhythmia, $10 mm Hg fall in
systolic pressure or achieving maximal predicted heart rate
(220 2 age). ST-segment depression was considered to be
significant when a $1-mm horizontal or down-sloping
depression occurred 0.08 s after the J point, when compared
with baseline.
At peak of exercise, 37 MBq of Tl-201 per 25 kg body
weight (without exceeding 111 MBq) was injected intrave-
nously; Exercise was then prolonged for 1 min at the same
workload. Stress imaging was initiated 10 to 15 min later,
and redistribution imaging 3 to 5 h later. For the 177
patients (50%) who underwent the test since 1988, a Tl-201
activity, corresponding to one third of that given at exercise,
was reinjected 10 min before redistribution imaging (26).
The technique to acquire, reconstruct and analyze the
SPECT images has been detailed elsewhere (4,27). Briefly,
the reconstructed slices were analyzed visually by a blinded
experienced observer using both a 20-segment division of
the left ventricle and a four-point grading system: 0, normal
uptake; 1, equivocal; 2, moderate, and 3, severe reduction of
uptake. Total extent of exercise defects was determined by
the percentage of segments showing an uptake score $2 on
exercise Tl-201 tomograms, and extent of reversible defects
was determined by the percentage of segments with exercise
defects which had a $1-point decrease of the uptake score
on the rest acquisition.
Follow-up data. Follow-up data were obtained by mailed
questionnaires or telephone interviews, from the patients,
their families or attending physicians. Cardiac death and
myocardial infarction were defined as major ischemic
events.
Cardiac death was defined as a death of demonstrated
cardiac origin or unknown origin, and diagnosis of myocar-
dial infarction was based on the presence of at least two of
the following: prolonged ($20 min) chest pain, electrocar-
diographic abnormalities (new Q-wave or ST-segment el-
evation) or enzyme changes (more than twice the upper
limit of normal).
Statistical analysis. Continuous variables were expressed
as mean 6 SD and compared with Mann-Whitney tests.
Discrete variables were expressed as percentages and com-
pared with chi-square or Fisher exact tests when appropri-
ate.
The relations between baseline data (listed in Table 1)
and the subsequent occurrence of events were analyzed by
means of Cox proportional hazards regression models (28)
(BMDP Statistical Software Inc., Los Angeles, Califor-
nia [29]). The events taken into account were the major
cardiac events (cardiac death and myocardial infarction) but
also, in an additional analysis, the overall cardiac events
including both major events and cardiac interventions (car-
diac surgery and coronary angioplasty). Patients who had
subsequent cardiac surgery or coronary angioplasty were
always censored at the date of their intervention. The
chi-square value was calculated from the log of the ratio of
maximal partial likelihood functions, and variables for
Abbreviations and Acronyms
CHD 5 coronary heart disease
CI 5 confidence interval
LAD 5 left anterior descending coronary artery
RR 5 relative risk
SPECT 5 single photon emission computed tomography
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which p values of the univariate chi-square test were less
than 0.05 were considered to be significant predictors of
prognosis.
A multivariate ascending Cox regression analysis was
performed stepwise to assess the additional prognostic
information provided by Tl-201 SPECT compared with
that already provided by the other investigations. The
assumed limit for significance to enter a variable was 0.05
and the limit to remove a variable was 0.10. The Cox model
was initially only applied to the significant univariate pre-
dictors from clinical history, exercise testing and catheter-
ization. The selected independent predictors were then
forced to remain in the model, whereas SPECT variables
were tried and entered at a p value of 0.05.
The Cox model analyses were applied in the overall
population, and in a comparative way, in each of the three
groups (GI, GII and GIII). Finally, to provide a more
precise evaluation of the effect of the further prescription of
each of the three medication classes after the test, univariate
Cox analysis was applied comparatively between patients
who were without a given class both at exercise test and at
follow-up and those who had only this class added for
follow-up. The relative risks (6SD) provided by the Cox
analyses of the baseline variables in the different groups were
compared by means of a one-tail test on a table of critical
values of the normal distribution, the null hypothesis being
that the relative risks might be lowered in patients for whom
antianginal medications were added after the test.
RESULTS
Exercise SPECT was performed on antianginal treatment
in 198 patients (56%), and an antianginal treatment was
prescribed at hospital discharge after the test in 331 (94%)
(Table 2). When comparing exercise test data between
patients with (n 5 81) and those without (n 5 271)
beta-blockers at the time of exercise, there was a significant
difference only for maximal heart rate (125 6 22 vs. 144 6
21 bpm, p , 0.0001) and maximal systolic blood pressure
(178 6 29 vs. 185 6 28 mm Hg, p 5 0.04).
GI comprised 136 patients (39%). In most (89%) of the
remaining 216 patients, additional classes of antianginal
Table 1. Baseline Characteristics: Description in the Overall Population and Comparison Between the Three Groups
Overall
(n 5 352)
GI Patients
(n 5 136)
GII Patients
(n 5 79)
GIII Patients
(n 5 113)
Clinical and ECG data
Age (yr) 56 6 9 56 6 9 54 6 10 56 6 8
Male gender 324 (92%) 123 (90%) 75 (95%) 103 (91%)
Diabetes mellitus 57 (16%) 21 (15%) 8 (10%) 26 (23%)
History of infarction 267 (76%) 102 (75%) 62 (78%) 83 (73%)
Recent (#3 months) 207 (59%) 77 (55%) 54 (68%) 65 (58%)
Angina 177 (50%) 63 (46%) 39 (49%) 61 (54%)
Class III–IV angina 108 (31%) 40 (29%) 24 (30%) 37 (33%)
Q waves 213 (61%) 78 (57%) 52 (66%) 18 (57%)
Anterior Q wave 102 (29%) 40 (29%) 23 (29%) 29 (26%)
Left bundle branch block 7 (2%) 4 (3%) 1 (1%) 2 (2%)
Exercise Tl-201 SPECT
Maximal heart rate (beats/min) 140 6 22 140 6 21* 144 6 24† 137 6 21
Increase in heart rate (beats/min) 61 6 20 60 6 19 63 6 22 58 6 20
ST-segment depression 124 (35%) 48 (35%) 29 (37%) 39 (35%)
Angina 74 (21%) 33 (24%) 16 (20%) 18 (16%)
Positive test 154 (44%) 64 (47%) 32 (41%) 45 (40%)
Abnormal exercise SPECT 320 (91%) 124 (91%) 74 (94%) 98 (87%)
Defects extent (% of LV area)
Exercise defect 26 6 17 25 6 17 28 6 16 24 6 19
Reversible defect 9 6 10 9 6 10 8 6 11 7 6 10
Irreversible defect 17 6 16 16 6 15 20 6 17 17 6 17
Cardiac catheterization
LV ejection fraction‡ 54 6 14 55 6 15 55 6 13 53 6 13
LMCA stenosis 3 (1%) 0 (0%) 1 (1%) 2 (2%)
Proximal LAD stenosis 63 (18%) 30 (22%)† 16 (20%)† 11 (10%)
No. of diseased vessels
With $50% stenosis 1.5 6 0.8 1.6 6 0.8 1.5 6 0.7 1.4 6 0.8
With $70% stenosis 1.0 6 0.8 1.1 6 1.1 1.1 6 0.7 0.9 6 0.7
*p , 0.05 compared with GII. †p , 0.05 compared with GIII. ‡Calculated on contrast LV angiography in 342 patients.
ECG 5 electrocardiographic; LAD 5 left anterior descending coronary artery; LMCA 5 left main coronary artery; LV 5 left ventricular; SPECT 5 single photon emission
computed tomography.
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medications were introduced between the test and hospital
discharge. The added medications included beta-blockers in
79 patients (GII), and did not include beta-blockers in 113
patients (GIII).
The antianginal treatment was decreased between exer-
cise SPECT and follow-up in only 24 patients. Most of
them (79%) had no evidence of myocardial ischemia at
Tl-201 SPECT; the reasons for antianginal medications
withdrawal could not be ascertained retrospectively in all
patients.
Baseline characteristics. The patients’ baseline character-
istics are detailed in Tables 1 and 2. Regarding antianginal
treatments, there were obvious differences among the three
groups in accordance with the way they were defined (Table
2). For example, GII and GIII patients, in whom antian-
ginal medications had been added after exercise SPECT,
also had, compared with GI patients, a higher number of
antianginal medications at follow-up and a lower number of
antianginal medications at exercise SPECT (Table 2).
In addition, because none of them had beta-blockers at
exercise SPECT, GII patients reached higher values of
maximal heart rates at exercise than those from GI or GIII
(Table 1). All other baseline characteristics (Table 1) were
similar in the three groups, except for the frequency of
proximal left anterior descending coronary artery (LAD)
stenosis, which was lower in GIII than in GI or GII.
Outcome events. During a follow-up of 5.3 6 1.6 years,
30 patients (9%) had cardiac death, 45 (13%) had major
ischemic events (cardiac death or infarction), 57 (16%) had
cardiac interventions (coronary angioplasty: 24, bypass
grafting: 35 [after a previous angioplasty in five cases], heart
transplantation: 4 [after a previous angioplasty in one case])
and 100 (28%) had a cardiac event (major ischemic event
and/or cardiac intervention).
There were no significant differences between the three
groups in the follow-up durations (GI: 5.2 6 1.7 years, GII:
5.3 6 1.3 years, GIII: 5.4 6 1.8 years) and in the rates
of nonfatal myocardial infarction (GI: 5%, GII: 6%, GIII:
3%). Although the differences were not statistically signifi-
cant, there were trends toward lower rates in GII than in
GI or GIII, when considering cardiac death (GI: 10%, GII:
5%, GIII: 12%), major ischemic events (GI: 15%, GII: 11%,
GIII: 14%), cardiac interventions (GI: 20%, GII: 11%, GIII:
19%) and cardiac events (GI: 33%, GII: 23%, GIII: 33%).
Univariate prediction of major ischemic events. The risk
of major events was not significantly related to the prescrip-
tion of beta-blockers, calcium antagonists or nitrates, even
when the analyses were restricted to either GI, GII or GIII.
Significant variables by univariate analysis are listed in
Table 3. Among the clinical and exercise testing data,
significant predictors were as follows: increase in heart rate
(p 5 0.01), age (p 5 0.025) and a positive exercise test (p 5
0.045). The relative risks associated with these three param-
eters were not significantly different when determined in
either GI, GII or GIII.
Among catheterization data, the main predictors of major
ischemic events were: left ventricular ejection fraction (p ,
0.0001), number of $70% diseased vessels (p 5 0.0001) and
presence of a stenosis on the proximal LAD (p 5 0.0049)
(Table 3). As illustrated in Figure 1, the relative risks
provided by the Cox models for each of these parameters
were similar in the three groups.
Single photon emission computed tomography predictors
were: total extent of exercise defects (p , 0.0001), extent of
reversible defects (p 5 0.0028) and extent of irreversible
Table 2. Classes of Antianginal Medications Given at Exercise Tl-201 SPECT and
Subsequently Prescribed for Follow-up: Description in the Overall Population and Comparison
Between the Three Groups
Overall
(n 5 352)
GI Patients
(n 5 136)
GII Patients
(n 5 79)
GIII Patients
(n 5 113)
Exercise Tl-201 SPECT
Presence of AM 198 (56%) 118 (87%)*† 18 (23%) 39 (34%)
Number of classes of
AM
0.9 6 0.9 1.4 6 0.8*† 0.3 6 0.7 0.4 6 0.5
Beta-blockers 81 (23%) 42 (31%)*† 0 (0%)† 21 (19%)
Calcium antagonists 106 (30%) 67 (49%)*† 15 (19%) 11 (10%)
Nitrates or molsidomine 124 (35%) 83 (61%)*† 12 (15%) 8 (8%)
Follow-up
Presence of AM 331 (94%) 118 (87%)*† 79 (100%) 113 (100%)
Number of classes of
AM
1.5 6 0.7 1.4 6 0.8*† 1.8 6 0.8 1.6 6 0.6
Beta-blockers 151 (43%) 42 (31%)*† 79 (100%)† 19 (17%)
Calcium antagonists 175 (50%) 67 (49%)*† 25 (32%)† 83 (73%)
Nitrates or molsidomine 203 (58%) 83 (61%)*† 36 (46%)† 84 (74%)
*p , 0.05 compared with GII. †p , 0.05 compared with GIII.
AM 5 antianginal medications; SPECT 5 single photon emission computed tomography.
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defects (p 5 0.0026). The relative risk related to extent of
irreversible defect was similar when determined in either
GI, GII, or GIII (Table 3, Fig. 1). In contrast, the relative
risk related to the extent of reversible defects was signifi-
cantly lower when determined in GII than in either GI (p 5
0.045) or GIII (p 5 0.015) (Table 3, Fig. 1). Although the
extent of reversible defect was a potent predictor in both GI
(p 5 0.0045) and GIII (p 5 0.0037), no such relationship
was observed in GII (p 5 0.54), where the only significant
SPECT predictor was the extent of irreversible defects
(Table 3). The extent of reversible SPECT defect remained
a predictor (p 5 0.045) when the analysis in GI was
restricted to patients who had beta-blockers (n 5 42; four
major events). A similar subgroup analysis could not be
done in GIII; 19 were on beta-blockers and only one had a
major event.
These results are illustrated in Figure 2 by the major-
events–free survival curves, stratified as a function of pres-
ence or absence of a reversible exercise defect at baseline,
significant differences being reached in both GI and GIII,
but not in GII.
Influence of the type of events analyzed or of the
duration of follow-up. When all cardiac events, including
cardiac interventions, were taken into account, extent of
reversible Tl-201 SPECT defect remained a potent predic-
Figure 1. Main prognostic indicators: comparisons of the relative
risks (695% confidence interval) provided by the Cox analyses
performed in the three groups: GI (solid circles), GII (open
circles) and GIII (striped circles). * p , 0.05. LAD 5 left
anterior descending coronary artery; LV 5 left ventricle.
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tor in GI (p 5 0.017; relative risk [RR] [95% confidence
interval (CI)]: 1.03 [1.01 to 1.06]) and in GIII (p 5 0.034;
RR [95% CI]: 1.03 [1.00 to 1.06], but was still totally
unrelated to the occurrence of events in GII (p 5 0.34; RR
[95% CI]: 0.98 [0.93 to 1.03]). In all groups taken together,
extent of irreversible defect lost its prognostic significance
for all cardiac events.
When the prediction of major events (cardiac death and
myocardial infarction) was restricted to the initial two-year
follow-up period (22 major events), the extent of reversible
defect was still a significant predictor in GI (p 5 0.0093;
RR [95% CI]: 1.06 [1.02 to 1.11]) and not in GII (p 5
0.38; RR [95% CI]: 1.04 [0.96 to 1.13]), whereas the result
obtained in GIII was of borderline significance (p 5 0.062;
RR [95% CI]: 1.04 [1.00 to 1.10]). In all groups taken
together, extent of irreversible defect was not a significant
predictor of major events over the first two years of
follow-up.
Multivariate prediction of major ischemic events. Mul-
tivariate analysis was first applied to the significant clinical,
exercise test and catheterization data listed in Table 3. In
the overall population, the main independent predictors of
major events were: 1) left ventricular ejection fraction (p 5
0.0024; RR [95% CI]: 0.97 [0.95 to 0.99]); 2) number of
$70% diseased vessels (p 5 0.012; RR [95% CI]: 1.73 [1.13
to 2.64]); 3) proximal LAD stenosis (p 5 0.021; RR [95%
CI]: 2.23 [1.15 to 4.32]), and 4) age: (p 5 0.023; RR [95%
CI]: 1.04 [1.00 to 1.08]).
Compared with the prediction provided by this model,
the extent of reversible defects was the sole SPECT variable
providing significant additional information in the analysis
performed in the overall population (p 5 0.017) and also in
both subgroup analyses performed in GI (p 5 0.020) and
GIII (p 5 0.026). However, no SPECT variable provided
significant additional information in the analysis performed
in GII (p 5 0.70 for extent of reversible defects) (Fig. 3).
Analysis of the specific impact of each antianginal class.
To provide a more direct analysis of the impact related to
the prescription of beta-blockers, only patients without
beta-blockers on the day of the test were kept in the analysis
(n 5 271; 39 major events), and patients for whom
beta-blockers were added after the test (n 5 79) were
Figure 2. Comparison, inside each of the three groups, of the Kaplan-Meier major-event–free survival curves, between patients who had
(solid squares) and those who did not have (open circles) significant exercise ischemia at baseline (reversible defect .5% of left ventricle).
Number below the abscissa 5 number of event-free patients at each 20-month follow-up interval.
Figure 3. Incremental prognostic value of extent of reversible
Tl-201 single photon emission computed tomography (SPECT)
defects, relative to those provided by the combination of clinical,
exercise testing and catheterization data. Analysis was performed
in the three groups (GI, GII and GIII). The initial models
included: left ventricular ejection fraction, number of $70%
diseased vessels, proximal left anterior descending artery stenosis
and age. In each group, total chi-square values are shown for the
initial models (hatched bars) and for the final models obtained
after the addition of extent of reversible Tl-201 SPECT defects
(solid bars).
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compared with the others (n 5 192). The extent of
reversible defect was still the sole baseline variable for which
the relative risk showed a significant difference between the
groups (RR [6 95% CI] per percent of left ventricle,
addition of beta-blockers: 0.98 [0.92 to 1.05] vs. no addition
of beta-blockers: 1.05 [1.02 to 1.07], p , 0.05).
In contrast, when considering the patients who were
without calcium antagonists on the day of the test (n 5 246;
30 major events), there was no difference in the risk related
to extent of reversible defect between that determined in
patients for whom calcium antagonists were added after the
test (n 5 89; RR [95% CI]: 1.04 [1.00 to 1.07]) and that
determined in the others (n 5 157; RR [95% CI]: 1.03
[1.00 to 1.07]).
In a similar way, in patients who were not on nitrates or
molsidomine on the day of the test (n 5 228; 22 major
events), there was no difference in the relative risk related to
the extent of reversible defect between that determined in
patients for whom nitrates or molsidomine were added after
the test (n 5 104; RR [95% CI]: 1.02 [0.99 to 1.06]) and
that determined in the others (n 5 124; RR [95% CI]: 1.02
[0.96 to 1.09]).
DISCUSSION
In patients with CHD, myocardial ischemia is an important
prognostic factor which can be corrected by appropriate
therapeutic interventions. Exercise SPECT gives the oppor-
tunity to assess the ischemia induced by a physiologic stress,
and has been demonstrated to provide strong prognostic
information (1–9) complementary to that of cardiac cathe-
terization (2,4). Exercise ischemia as assessed by scintigra-
phy (reversible defects) has been shown to correlate with a
poorer prognosis and to be a more accurate predictor than
ischemic signs on exercise electrocardiography (1,4,5).
Exercise SPECT under daily life antianginal medica-
tions. Because the exercise ischemia, evidenced by SPECT,
may be decreased by antianginal medications (13–18), the
withdrawal of such medications is generally recommended
for patients having exercise SPECT to detect CHD. How-
ever, when the exercise SPECT is performed on antianginal
treatment, it has been shown that a normal result conferred
an excellent long-term outcome (30). Conversely, for the
purpose of prognostic determination, it is likely that per-
forming the exercise SPECT on daily life antianginal
treatment will provide more potent information, as it will
show the perfusion abnormalities likely to occur during daily
life.
Exercise SPECT was performed on the subsequently
ordered daily life treatment in 39% of our patients (GI). In
this subgroup, the SPECT variables, including that reflect-
ing the amount of ischemia (reversible defect extent), were
strongly correlated with prognosis, and exercise SPECT
provided clearly original and complementary prognostic
information compared with cardiac catheterization. This
finding gives evidence of the high prognostic value of
exercise SPECT when performed in such daily life condi-
tions.
Impact of the further addition of beta-blocking antian-
ginal medications. A definite trend toward lower rates
of cardiac death and of cardiac interventions was observed
in patients who had a further addition of beta-blockers
(GII). Possibly because of the relatively small sizes of the
groups, however, the differences with the other groups
were not significant. Nevertheless, because of the retro-
spective and nonrandomized design of our study, it was
difficult to directly compare the event rates between the
groups, and only the relative risk of events were used
for those comparisons. When so determined, only the
risk related to stress ischemia (reversible defect extent),
showed significant differences between the groups. It was,
indeed, significantly lower in patients for whom antian-
ginal medications including beta-blockers were added
after exercise SPECT. Therefore, for a given amount of
exercise ischemia, the risk of major events was signifi-
cantly lowered when medications including beta blockers
had been subsequently added.
This observation cannot be explained by a less severe
ischemic risk at baseline in the GII patients. Indeed,
compared with the patients who had no change in antian-
ginal treatment (GI), those who had a further addition of
beta-blockers (GII) had equivalent baseline characteristics,
even for variables related to the ischemic risk (reversible
defect extent, positive exercise testing). Finally, the number
of classes of antianginal medications prescribed after the test
was higher in GII than in GI, giving evidence that GII
patients were not considered at a lower ischemic risk after
having performed the baseline investigations.
Contrary to what was observed for exercise SPECT
ischemia, all of the other conventional prognostic parame-
ters, such as those reflecting the amount of irreversibly
damaged myocardium (irreversible defect extent, left ven-
tricular ejection fraction) or those reflecting the severity of
coronary artery disease (proximal LAD stenosis, number of
diseased vessels), had a similar prognostic significance in the
three groups. Therefore, a comprehensive analysis of our
results suggests that there was a significant prognostic effect
of beta-blockers principally related to the risk related to
stress ischemia.
The heart protection documented for beta-blockers in a
certain subset of CHD patients is considered to be mainly
related to an anti-ischemic action, but also to their potential
antiarrhythmic effects including the prevention of ventricu-
lar fibrillation during ischemia (23). The anti-ischemic
action of beta-blockers has been documented in a number of
exercise scintigraphic studies: propranolol has been reported
to decrease perfusion abnormalities in 57% to 100% of cases
(13–15) and to erase any abnormalities in 27% (15). In a
recent Tl-201 SPECT study performed after myocardial
infarction, it was observed that oral therapy including
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beta-blockers led to a reduction in exercise ischemia equiv-
alent to that provided by coronary angioplasty (19).
The influence of the further addition of non– beta-
blocking antianginal medications. The exercise ischemia
evidenced by scintigraphy can also be decreased by the oral
administration of non–beta-blocking antianginal medica-
tions; limited effects were observed for nifedipine (16) or
isosorbide-5-mononitrate (17), but a more pronounced
effect was documented at short term for isosorbide dinitrate
(16,18). In our group comparisons, however, the risk related
to stress ischemia (reversible defect extent) was unchanged
in patients who had a subsequent administration of only
non–beta-blocking antianginal medications (GIII). This
suggests a specific role for beta-blockers. This finding is in
keeping with the observation that only beta-blocking anti-
anginal medications have been consistently reported to
improve prognosis in certain subsets of CHD patients
(20–23).
Study limitations. Although we have observed that exer-
cise SPECT ischemia was a strong predictor for patients
who had the test while on their daily life treatment (GI),
few of them were on beta-blockers. Therefore, the prognos-
tic value of exercise SPECT performed on beta-blocker
therapy remains to be more extensively analyzed.
In the present study, no control SPECT was performed
after the changes in antianginal medications. Therefore, we
were not in a position to determine whether the decreased
prognostic impact of exercise ischemia in patients who had
a further addition of beta-blockers was directly related to an
improvement in exercise perfusion, or whether other pro-
tective effects of beta-blockers such as their antiarrhythmic
effects might have played a role.
In addition, the subsequent sequential changes in antian-
ginal therapy during follow-up were not taken into account,
and this was because this information could not be precisely
obtained several years later in a number of cases. However,
we found essentially similar results, despite a much lower
number of analyzed events, when the analysis was restricted
to the initial two years of follow-up and thus, when
medications were likely to be unchanged for most of
patients. Furthermore, the same limitation applies to pre-
vious prospective randomized studies, in which initial treat-
ment with beta-blockers has been reported to improve
prognosis (20–23), even at long-term follow-up ($5 years)
and despite the fact that a high number of patients had
modified their medications (31,32). Our study shows that
the prescription of beta-blockers is sufficient to have an
influence on the deleterious prognostic significance of the
stress (Tl-201 SPECT) ischemia, whereas it has no effect on
the other nonischemic prognostic parameters.
Our analyses were mainly based on the prediction of
major events (cardiac death, infarction) because other
events, such as cardiac interventions, are subjective and are
strongly influenced by the results of the baseline investiga-
tions (especially coronary angiography for myocardial revas-
cularization). Nevertheless, in an additional analysis that
included cardiac interventions, we found equivalent results
on the SPECT prognostic parameters.
Our population of stable and medically treated patients
constitutes a selected low risk subgroup, and extrapolations
to other populations of CHD patients are uncertain. Most
of our patients had a history of infarction, possibly because
those without such a history and who have significant
coronary artery disease are less frequently referred to med-
ical therapy only. Therefore, it may be wondered whether
the protective effect of beta-blockers predominantly acts in
the setting of residual ischemia after infarction. This hy-
pothesis, which would require a much larger population to
be analyzed, is strengthened by the consideration that it is
mainly in postinfarction patients that beta-blockers have
been demonstrated to improve prognosis (20–23,31,32).
Also, it might be questioned whether beta-blockers would
have a similar effect in patients having a higher ischemic
risk, such as those referred for myocardial revascularization.
Although further studies will be required to clarify these
points, the present data document that, when including
beta-blockers, oral antianginal therapy is able to have a
favorable impact on the deleterious prognostic effect of
stress ischemia.
Conclusions. This study, performed in patients with med-
ically treated CHD, gives evidence that: 1) exercise ischemia
documented by Tl-201 SPECT has a strong prognostic
significance when the test is performed on the same anti-
anginal treatment as that subsequently prescribed; and
moreover 2) the introduction of antianginal medications,
when including beta-blockers, appears to have a favorable
influence on the deleterious prognostic effect of exercise
ischemia.
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